Skip to main content

Alaunos Therapeutics, Inc 10-Q for FY2026 Q3

Alaunos Therapeutics, Inc. (TCRT)

10-Q 2026-11-16 For: 2026-09-30
View Original
Added on November 16, 2026

About this 10-Q

Alaunos Therapeutics, Inc filed this 10-Q on November 16, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Alaunos Therapeutics plans VLR199 IND or CTA submission in the second half of 2027, with proof-of-concept data expected in 2028. VLR360 also targets 2028 data, while VLR247 or VLR258 IND submission is planned for the first half of 2028. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$0
compared with $0 a year earlier
Net loss
$772K
compared with a net loss of $1.16M a year earlier
Diluted EPS
-$0.31
compared with -$0.55 a year earlier